Here are the 10-K annual reports from Standard BioTools Inc. (LAB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LAB filings page.
Standard BioTools Inc. files its annual report describing a life sciences tools business focused on proteomics and genomics platforms, including CyTOF, Hyperion and Biomark systems. The company sold its SomaScan proteomics subsidiaries to Illumina under a Stock Purchase Agreement signed June 22, 2025, with the transaction closing January 30, 2026, and now reports those operations as discontinued.
For 2025, it highlights a more than $70 billion addressable market in life science research tools and notes that $56.9 million, or 67% of total revenue, came from customers outside the United States. Standard BioTools reports a 2025 net loss of $74.9 million and an accumulated deficit of $1.3 billion as of December 31, 2025, while emphasizing ongoing restructuring and cost actions.
The company details competitive dynamics against major life science tool providers, dependence on key suppliers, extensive global regulatory and data-privacy obligations, and numerous risk factors ranging from market volatility and acquisitions to litigation related to its merger with SomaLogic. As of March 12, 2026, it had 390,071,506 common shares outstanding, 389 employees worldwide, and a non‑affiliate equity market value of approximately $290.9 million as of June 30, 2025.